JP2009536629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536629A5 JP2009536629A5 JP2009508193A JP2009508193A JP2009536629A5 JP 2009536629 A5 JP2009536629 A5 JP 2009536629A5 JP 2009508193 A JP2009508193 A JP 2009508193A JP 2009508193 A JP2009508193 A JP 2009508193A JP 2009536629 A5 JP2009536629 A5 JP 2009536629A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- inhibitor
- agonist
- inhibitors
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 21
- 239000000556 agonist Substances 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 3
- -1 O-phenyl Chemical group 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 229940086609 Lipase inhibitor Drugs 0.000 claims 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 2
- 108091006300 SLC2A4 Proteins 0.000 claims 2
- 102100038803 Somatotropin Human genes 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- 102100036506 11-beta-hydroxysteroid dehydrogenase 1 Human genes 0.000 claims 1
- 101710186107 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102000004146 ATP citrate synthases Human genes 0.000 claims 1
- 108090000662 ATP citrate synthases Proteins 0.000 claims 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 108010018763 Biotin carboxylase Proteins 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 claims 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 claims 1
- 102100032165 Corticotropin-releasing factor-binding protein Human genes 0.000 claims 1
- 101710093056 Corticotropin-releasing factor-binding protein Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 229940121889 Endothelin A receptor antagonist Drugs 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 claims 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 101800002068 Galanin Proteins 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims 1
- 229940121931 Gluconeogenesis inhibitor Drugs 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims 1
- 102000001284 I-kappa-B kinase Human genes 0.000 claims 1
- 108060006678 I-kappa-B kinase Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 229940122014 Lyase inhibitor Drugs 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010015181 PPAR delta Proteins 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 229940122294 Phosphorylase inhibitor Drugs 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 108091006299 SLC2A2 Proteins 0.000 claims 1
- 101710181093 Sodium-dependent glucose transporter 1 Proteins 0.000 claims 1
- 102100029795 Sodium-dependent glucose transporter 1 Human genes 0.000 claims 1
- 102000000019 Sterol Esterase Human genes 0.000 claims 1
- 108010055297 Sterol Esterase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 claims 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 claims 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 claims 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 claims 1
- 102000005630 Urocortins Human genes 0.000 claims 1
- 108010059705 Urocortins Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000003392 amylase inhibitor Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003062 endothelin A receptor antagonist Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229940124828 glucokinase activator Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 239000002697 lyase inhibitor Substances 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 239000000777 urocortin Substances 0.000 claims 1
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006021878A DE102006021878A1 (de) | 2006-05-11 | 2006-05-11 | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PCT/EP2007/003806 WO2007131622A1 (de) | 2006-05-11 | 2007-04-30 | Phenylamino-benzoxazol substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536629A JP2009536629A (ja) | 2009-10-15 |
| JP2009536629A5 true JP2009536629A5 (enExample) | 2010-06-17 |
Family
ID=38371048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508193A Pending JP2009536629A (ja) | 2006-05-11 | 2007-04-30 | フェニルアミノ−ベンゾオキサゾール置換カルボン酸類、それらの製造方法、及び医薬品としての使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20090149519A1 (enExample) |
| EP (1) | EP2024347B1 (enExample) |
| JP (1) | JP2009536629A (enExample) |
| KR (1) | KR20090006846A (enExample) |
| CN (1) | CN101437805B (enExample) |
| AR (1) | AR060990A1 (enExample) |
| AU (1) | AU2007250213B2 (enExample) |
| BR (1) | BRPI0711448A2 (enExample) |
| CA (1) | CA2651660A1 (enExample) |
| CO (1) | CO6241107A2 (enExample) |
| CY (1) | CY1113177T1 (enExample) |
| DE (1) | DE102006021878A1 (enExample) |
| DK (1) | DK2024347T3 (enExample) |
| ES (1) | ES2391203T3 (enExample) |
| HR (1) | HRP20120829T1 (enExample) |
| IL (1) | IL195179A0 (enExample) |
| MA (1) | MA30402B1 (enExample) |
| MX (1) | MX2008014102A (enExample) |
| MY (1) | MY148258A (enExample) |
| NO (1) | NO20085068L (enExample) |
| NZ (1) | NZ572692A (enExample) |
| PL (1) | PL2024347T3 (enExample) |
| PT (1) | PT2024347E (enExample) |
| RS (1) | RS52450B (enExample) |
| RU (1) | RU2434003C2 (enExample) |
| SI (1) | SI2024347T1 (enExample) |
| TW (1) | TW200812987A (enExample) |
| UY (1) | UY30338A1 (enExample) |
| WO (1) | WO2007131622A1 (enExample) |
| ZA (1) | ZA200808490B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
| AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| AU2008241490B2 (en) | 2007-04-16 | 2011-07-21 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2702047C (en) | 2007-10-10 | 2012-04-17 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
| WO2009145829A1 (en) * | 2008-04-01 | 2009-12-03 | University Of Massachusetts | Type iii secretion inhibitors, analogs and uses thereof |
| US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| WO2010045258A2 (en) | 2008-10-15 | 2010-04-22 | Amgen Inc. | Spirocyclic gpr40 modulators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013039140A1 (ja) * | 2011-09-14 | 2013-03-21 | 第一三共株式会社 | 縮合へテロ環誘導体 |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
| EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| MX2021007967A (es) | 2019-01-11 | 2021-09-21 | Naegis Pharmaceuticals Inc | Inhibidores de síntesis de leucotrienos. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1491863A (en) * | 1973-10-23 | 1977-11-16 | Lilly Industries Ltd | 2,5-or 2,6-disubstituted benzoxazoles |
| US4025637A (en) * | 1973-10-23 | 1977-05-24 | Lilly Industries, Ltd. | 2,5 OR 2,6 Disubstituted benzoxazoles |
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5296486A (en) * | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
| CA2144763A1 (en) * | 1992-10-14 | 1994-04-28 | George D. Hartman | Fibrinogen receptor antagonists |
| WO1998040381A1 (en) * | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| JP2002521375A (ja) * | 1998-07-23 | 2002-07-16 | アストラゼネカ アクチエボラーク | 化合物 |
| DE60027700T2 (de) * | 1999-02-16 | 2007-05-03 | Aventis Pharma Ltd., West Malling | Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden |
| GB0001346D0 (en) * | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
| MXPA03003829A (es) * | 2000-11-04 | 2003-07-28 | Aventis Pharma Ltd | Acidos alcanoicos substituidos. |
| TWI312779B (enExample) * | 2000-12-28 | 2009-08-01 | Daiichi Seiyaku Co | |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| JP2006056830A (ja) * | 2004-08-20 | 2006-03-02 | Dai Ichi Seiyaku Co Ltd | ２−アリールアミノベンゾオキサゾール誘導体 |
-
2006
- 2006-05-11 DE DE102006021878A patent/DE102006021878A1/de not_active Withdrawn
-
2007
- 2007-04-30 AU AU2007250213A patent/AU2007250213B2/en not_active Expired - Fee Related
- 2007-04-30 RU RU2008148838/04A patent/RU2434003C2/ru not_active IP Right Cessation
- 2007-04-30 MY MYPI20084472A patent/MY148258A/en unknown
- 2007-04-30 MX MX2008014102A patent/MX2008014102A/es active IP Right Grant
- 2007-04-30 RS RS20120395A patent/RS52450B/sr unknown
- 2007-04-30 HR HRP20120829TT patent/HRP20120829T1/hr unknown
- 2007-04-30 WO PCT/EP2007/003806 patent/WO2007131622A1/de not_active Ceased
- 2007-04-30 DK DK07724733.6T patent/DK2024347T3/da active
- 2007-04-30 PT PT07724733T patent/PT2024347E/pt unknown
- 2007-04-30 BR BRPI0711448-6A patent/BRPI0711448A2/pt not_active IP Right Cessation
- 2007-04-30 PL PL07724733T patent/PL2024347T3/pl unknown
- 2007-04-30 CA CA002651660A patent/CA2651660A1/en not_active Abandoned
- 2007-04-30 CN CN2007800162659A patent/CN101437805B/zh not_active Expired - Fee Related
- 2007-04-30 JP JP2009508193A patent/JP2009536629A/ja active Pending
- 2007-04-30 NZ NZ572692A patent/NZ572692A/en not_active IP Right Cessation
- 2007-04-30 ES ES07724733T patent/ES2391203T3/es active Active
- 2007-04-30 SI SI200731028T patent/SI2024347T1/sl unknown
- 2007-04-30 KR KR1020087027644A patent/KR20090006846A/ko not_active Ceased
- 2007-04-30 EP EP07724733A patent/EP2024347B1/de active Active
- 2007-05-09 AR ARP070102008A patent/AR060990A1/es not_active Application Discontinuation
- 2007-05-09 TW TW096116362A patent/TW200812987A/zh unknown
- 2007-05-10 UY UY30338A patent/UY30338A1/es not_active Application Discontinuation
-
2008
- 2008-10-06 ZA ZA200808490A patent/ZA200808490B/xx unknown
- 2008-10-30 CO CO08116211A patent/CO6241107A2/es not_active Application Discontinuation
- 2008-11-05 MA MA31362A patent/MA30402B1/fr unknown
- 2008-11-09 IL IL195179A patent/IL195179A0/en unknown
- 2008-11-10 US US12/267,896 patent/US20090149519A1/en not_active Abandoned
- 2008-12-04 NO NO20085068A patent/NO20085068L/no not_active Application Discontinuation
-
2012
- 2012-10-12 CY CY20121100941T patent/CY1113177T1/el unknown
-
2013
- 2013-07-10 US US13/938,627 patent/US8748465B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536629A5 (enExample) | ||
| JP2009536626A5 (enExample) | ||
| JP2009536627A5 (enExample) | ||
| Stanifer et al. | Importance of type I and III interferons at respiratory and intestinal barrier surfaces | |
| RU2008148838A (ru) | Фениламинобензоксазолзамещенные карбоновые кислоты, способ их получения и их применение в качестве лекарственных средств | |
| US6680308B1 (en) | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | |
| RU2008105756A (ru) | Производные 1,4-бензотиазепин-1,1-диоксида, способ их получения, лекарственное средство, содержащее эти соединения и их применение в качестве гиполипидемических средств | |
| RU2010115748A (ru) | (карбоксилалкиленфенил) фенилоксаламиды, способ их получения и их применение в качестве лекарственного средства | |
| BRPI0413756A (pt) | composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica | |
| RU2010115747A (ru) | (циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства | |
| CN110325187A (zh) | 治疗流感的方法 | |
| RU2009120679A (ru) | Новый дифенилазетидинон, замещенный пиперазин-1-сульфокислотой, обладающий улучшенными фармакологическими свойствами | |
| WO2007139150A1 (ja) | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 | |
| HUE027064T2 (hu) | Fokozott immunstimuláns aktivitású, hidrofób T-analógokat tartalmazó CPG oligonukleotid-analógok | |
| CN115666570A (zh) | 瑞德西韦治疗方法 | |
| JP2007536229A (ja) | 体重減少に作用するための組成物 | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| RU2004108120A (ru) | Комбинированные препараты из арилзамещенных производных пропаноламина с другими биологически активными веществами и их применение | |
| EA200501680A1 (ru) | Фосфонатсодержащие антивирусные соединения (варианты), фармацевтическая композиция (варианты), способ ее получения (варианты), лекарственная форма на их основе и способы их применения в лечении заболеваний, способы ингибирования вирусного фермента (варианты) и рнк-зависимой рнк полимеразы (варианты) | |
| UA116992C2 (uk) | Лікування імуноопосередкованого захворювання (варіанти) | |
| EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
| RU2005128497A (ru) | Замещенные производные гексагидропиразино (1,2-а) пиримидин-4,7-диона, способы их получения и их применение в качестве лекарственных средств | |
| RU2005133631A (ru) | Новый дифенилазетидинон с улучшенными физиологическими свойствами, способы его получения, содержащие эти соединения лекарственные средства и их применение | |
| RU2009108280A (ru) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение | |
| KR20090121289A (ko) | 피라진 유도체를 함유하는 의약조성물 및 피라진 유도체를 조합하여 사용하는 방법 |